CYP1A2 and hepatocellular carcinoma: By decreasing the expression levels of HGF and HIF-1a (a transcriptional activator of MET, CYP1A2) was able to suppress MET activation and inhibit HCC cell viability, clonogenicity, migration, and invasion abilities in vitro and carcinogenesis in vivo [235].